Novavax stock
NVAXNASDAQNovavax, Inc., HealthcareISIN US6700024010
42Score 42 out of 100, Weak
Price and trend
53 / 100
Price history
+22% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 6.2% below it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 32% below its 52-week high. Largest decline in 20 years: 99% (February 2021 to February 2024).
Chart figures for advanced users
- SMA 50$10.57
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.34
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.22
- The lowest closing price of the last twelve months.
- Resistance$12.82
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Novavax, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.45B, is number 152 of 289 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $473.1M (down 57.9%) and adjusted earnings per share of −$0.05.
- MEQIRI Score 42 out of 100 (Weak): rank 508 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 99.9% in fiscal 2025, Biotechnology median −24.3%.
- More cash than debtCash $622.36M, financial debt $292.09M.Stability 64
Weaknesses
- DilutionShare count up 181% since 2020.Capital allocation 18
- Loss-makingLoss of $76.73M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$246.5M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 45 to 42.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 61.3% on the twelve months before. Up to 2023 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 18.8% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 94%, operating 50%, net 39%. Last 12 months: net −19%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 5 Nov 2026EPS reported −$0.19 (expected −$0.35)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 1,525.5% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.05+92.3%
- Revenue
- $473.1M+24.6%
- Earnings per share
- −$0.45−1,525.5%
- Revenue
- $246.08M−22.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +14.0%2026 outlook reiterated: adjusted total revenue of $230 million to $270 million, R&D and SG&A expense guidance unchanged.
“Today, we are reiterating our full year 2026 revenue framework and expect to achieve adjusted total revenues of between $230 million and $270 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Novavax
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 42
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Generate BiomedicinesGENB $1.61B36
- Immunocore HoldingsIMCR $1.57B45
- AbsciABSI $1.57B38
- Intellia TherapeuticsNTLA $1.48B33
- Nuvation BioNUVB $1.43B29
- AnaptysBioANAB $1.43B60
- Alto NeuroscienceANRO $1.42B41
- Ascentage Pharma Group InternationalAAPG $1.4B37
ETFs that hold Novavax
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.15% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.11% | 0.35% | €1.25B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 29 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.